Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cue Biopharma Inc V.CUE


Primary Symbol: CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.


NDAQ:CUE - Post by User

Bullboard Posts
Post by jpsartreanon Feb 28, 2008 8:12pm
226 Views
Post# 14569022

Lol...

Lol...Shawshank - you rode your Khan Resources turd from above $5.00 down well below $2.00 - so you're not in a position to gloat you fool.... CUE will have an NI 43-101 resource estimate released within the next few weeks. When it is released, one of us will be proven right, the other wrong... I've certainly placed my bet. Been accumulating CUE anywere I can under $1.50... Still have some open bids in now too... Cameco knew what they were getting into with CUE, and paid $1.80 per share and above... 20-25+ million pounds of respectable grade, ISL amenable, red-tape free uranium. Market valuing it at less than $2.00 per pound... Cameco will likely end up paying CUE $9/lb. and financing most of the development. If there are 25 million pounds at Yuty, CUE could have 10 million pounds of its own, unhedged production to sell. Could be worth ~$1,000,000,000 U.S. on top of the ~$135,000,000 U.S. that Cameco may end up paying them. CUE market cap currently just ~$30-$40 million Canadian. Speculative? Heck yes - there could be nothing at Yuty and this could go to $0.00 But Yuty could also be the jackpot I believe it to be - grades and thicknesses VERY similar to Kazahki deposits currently being developed by Cameco and Uranium One with production costs in the teens per pound, if not lower. Cue could very well move as high as $15-$20 within 5 years. I like those odds.
Bullboard Posts